Teva Pharmaceutical Industries TEVA
$39.23 +$0.69 (+1.79%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $39.23 0.00%
Open$38.46
Prev close$38.54
Day range$38.30 – $39.91
Volume6.81M
Market cap$45.77B
P/E (TTM)91.2
Dividend yield–
TEVA Stock News
Headlines matching Teva Pharmaceutical Industries or the TEVA ticker, most recent first.
- Leerink Partners Initiates Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Announces Target Price $45
- UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $48 Positive
- Goldman Sachs Initiates Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Announces Target Price $50
- Jefferies Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $40
- Evercore Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
- Scotiabank Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $40
- J.P. Morgan Sticks to Their Buy Rating for Teva (TEVA)
- J.P. Morgan Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
- BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $43 Positive
- Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 A.m. ET
- Teva Pharmaceutical Industries(TEVA.US) Director Sells US$14.36 Million in Common Stock
- Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
- UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $42
- Piper Sandler Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $44
- Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $42 Positive
No comments yet — be the first to weigh in on TEVA.
Sign in to join the discussion.